Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, telavancin (Vibativ®) cannot be endorsed for use within NHS Wales for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA). Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | telavancin (Vibativ®) | |
| Formulation | 250 mg powder for concentrate for solution for infusion, 750 mg powder for concentrate for solution for infusion | |
| Reference number | 719 | |
| Indication | For the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA). |
|
| Company | Clinigen Group Plc | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/01/2012 | |
| Date of issue | 09/01/2012 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||